Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)
02 December 2020 - 10:03PM
Edgar (US Regulatory)
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-230678
PROSPECTUS SUPPLEMENT NO. 1
TO PROSPECTUS DATED MAY 1, 2019
This Prospectus Supplement No. 1 supplements and amends the prospectus dated May 1, 2019 (the Prospectus), covering
the offering, issuance and sale of up to a maximum aggregate offering price of $50,000,000 (the Maximum Offering Price) of our common stock that may be issued and sold under a sales agreement with Cowen and Company, LLC
(the ATM Facility).
Effective as of December 1, 2020, we have reduced the Maximum Offering Price to $9,500,000.
As of the date of this prospectus supplement, no shares have been sold under the ATM Facility.
You should read this prospectus
supplement, together with additional information described under the headings Incorporation by Reference and Where You Can Find More Information in the Prospectus carefully before you invest in our securities.
Investing in our securities involves a high degree of risk. Before making any investment in these securities, you should consider
carefully the risks and uncertainties described in the section entitled Risk Factors beginning on page S-2 of the Prospectus.
The date of this prospectus supplement is December 1, 2020.
Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From Apr 2024 to May 2024
Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Unum Therapeutics Inc (NASDAQ): 0 recent articles
More Cogent Biosciences, Inc. News Articles